into we and Eatwell, quarter of on walk financial our I'd disclosed you the and like some go thank all to detail financials. second Officer, our results and business operational joining XXXX business for morning. Jenn, updates will Financial Vicki you, Today, updates. this Chief then Thank and through recent our
beginning focus business. commercial exclusively the ABECMA took to the decision Xseventy XXXX, strategic in of we At on the
the was believe the decision, or right we situation. continue was it it risk-free not an easy one While to given
we're have we beginning our see streamline succeeded our structure sheet the cost Nordisk dramatically positive and megaTAL hemophilia to with A reducing related Novo ABECMA. April structure cost sale driving to quarter what our proceeds technology strengthened oncology to the of million impact for controlling major financial sale second Regeneron and the R&D control from to what of are balance and can and out in business quarter, accomplishing also We of our this to We're growth in in June. resources $XX the Strengthening our the in set This and program in do: position, strategic pivot. dedicating we our
was our Novo deal another strategic streamline business. effort and to focus important transaction in the The further
team We changes incredible for who us we enacted have The are line our grateful the enable effort corner performance that thank members have treat ABECMA to work. to the in to earlier the to and their approval of following and since quarter them FDA's a focus Nordisk to XXX% energy on ABECMA Novo turned the report second and in patients. I'm U.S. pleased Xseventy transitioned that
quarter expected previously initiated as the and in revenue third our achieved in we launch. second as As guided, growth modest line we
a X-month As a time the we shared, enroll patient between roughly backlog, we've and patient we lag revenue. there's time that previously the recognize receives a and
the ABECMA. stopped the an who and seen also revenue prescribing of demand. were a patients have first process double-digit in indicator growth encouraged by in use leading While was impactor modest, growth apheresis, previously the in among step we increase undergoing sites We've
the launch received Additionally, our commercial messaging and well of backlog, providers. has a the efficacy consistent profile been on safety by
terms of the of what curve is to say to return soon growth. too it's the shape in While the
of myeloma. We've of the the ABECMA third play year, teams for second These the half launch and executing patients and that role important entered an ABECMA. indicators belief with has line BMS on support our living remain to the Xseventy ongoing focused now
the patients, on come. case to becomes line namely I'll of we turn well-established focused manufacturing believe with profile real and time shortly. clearly competitive in label population product. it earlier and return a But is the Q&A in in-spec optimistic launch setting, the about to for We results. continues to evidence to further for manageable second Our quarter a competitive [indiscernible] with is to that high efficacy about the ABECMA, to safety the world rapid a articulating profile data growth have Vicki? talk remain We'll class-exposed triple the we reproduced get high which need. and turnaround unmet real-world in now, profile over Vicki in rates With that is mature, months